Your browser does not support the video tag.
Platform to Patient
WuXi’s Laboratory Testing Division is a comprehensive integrated testing platform supporting customers across the full spectrum of their development efforts to deliver innovative medicines to patients.
R&D Sites in the US and China
Global IND Packages Completed
Global NDA Packages Completed
Clinical Centers in China
Years GMP and GLP Lab Experience
Validated Methods for Bioanalysis
Integrated Testing Platforms
Preclinical Drug Development
WuXi IND (WIND) combines technical experience, program management and regulatory expertise to facilitate submission of your IND package.
Clinical Drug Development
The Laboratory Testing Division can carry your compound from early discovery all the way through clinical trials, providing consistent, streamlined support across the lifecycle of your project.
Medical Device Testing
WuXi’s medical device testing experts provide end-to-end regulatory and technical support to bring your medical devices to market.
The Analytical Services Unit provides both early and late-phase analytical support, including integrated CMC services from IND to NDA and beyond.
Bioanalytical Services at the Laboratory Testing Division support
ADME, discovery biology, PK, PD and discovery toxicology from NCE through IND.
The Laboratory Testing Division provides comprehensive
ADMET solutions from high-throughput screening in discovery through drug development phases.
Our skilled team of toxicologists provide comprehensive safety assessments across a wide range of species and through various routes of administration.
WuXi Laboratory Testing Division: Propelling Innovation and Better Treatments for Patients
Read our thought leadership article “Creating Comprehensive Solutions through Laboratory Testing”
WuXi Experts Opinion on Impurity Research During Drug Development Webinar
4th Congress of the European Societies of Toxicology (EUROTOX 2018)
September 2 – 5